Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy

Journal of the American Society of Nephrology

Volumn 25, Issue 1, 2014, Pages 150-158

  Van Den Brand, Jan A J G ^a   Van Dijk, Peter R ^b   Hofstra, Julia M ^a   Wetzels, Jack F M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ISALA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; AZATHIOPRINE; CORTICOTROPIN; CREATININE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LIVER ENZYME; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLADDER CANCER; BREAST CANCER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM CANCER; DRUG MEGADOSE; DRUG THERAPY; FEMALE; FOLLOW UP; HEALTH CARE POLICY; HEART INFARCTION; HEMATOLOGIC MALIGNANCY; HEMATURIA; HEMODIALYSIS; HEMORRHAGIC CYSTITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPOALBUMINEMIA; IDIOPATHIC DISEASE; IDIOPATHIC MEMBRANOUS NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY CARCINOMA; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LUNG CANCER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MIDDLE AGED; NEPHROTIC SYNDROME; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; OVERALL SURVIVAL; PERIPHERAL VASCULAR DISEASE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEINURIA; REMISSION; RESTRICTIVE TREATMENT; SENSITIVITY ANALYSIS; SEVERE RENAL IMPAIRMENT; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT;

EID: 84891776380     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013020185     Document Type: Article

References (28)

1. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11-21, 2009
2. van den Brand JAJG, Hofstra JM, Wetzels JFM: Low-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 6: 2846-2853, 2011
3. du Buf-Vereijken PW, Branten AJ, Wetzels JF: Idiopathic membranous nephropathy: Outline and rationale of a treatment strategy.AmJ Kidney Dis 46: 1012-1029, 2005
4. Ponticelli C, Zucchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S, Sasdelli M, Redaelli B, Grassi C, Pozzi C, et al: A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 48: 1600-1604, 1995
5. Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, Joshi K, Sakhuja V: A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 18: 1899-1904, 2007
6. KDIGO Working Group: KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2: 186-197, 2012
7. Hofstra JM, Wetzels JF: Management of patients with membranous nephropathy. Nephrol Dial Transplant 27: 6-9, 2012
8. Aaltonen S, Honkanen E: Outcome of idiopathic membranous nephropathy using targeted stepwise immunosuppressive treatment strategy. Nephrol Dial Transplant 26: 2871-2877, 2011
9. Cattran DC, Reich HN, Kim SJ, Troyanov S: Have we changed the outcome in membranous nephropathy? A propensity study on the role of immunosuppressive therapy. Clin J AmSoc Nephrol 6: 1591-1598, 2011
10. du Buf-Vereijken PW, Feith GW, Hollander D, Gerlag PG, Wirtz JJ, Noordzij TC, Wetzels JF; Membranous Nephropathy Study Group: Restrictive use of immunosuppressive treatment in patients with idiopathic membranous nephropathy: high renal survival in a large patient cohort. QJM 97: 353-360, 2004
11. Hofstra JM, Branten AJ, Wirtz JJ, Noordzij TC, du Buf-Vereijken PW, Wetzels JF: Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: A randomized controlled trial. Nephrol Dial Transplant 25: 129-136, 2010
12. Statistics Netherlands: StatLine: survival rates by age and gender. Available at: http://statline.cbs.nl. Accessed November 2012
13. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry Group: Idiopathic membranous nephropathy: Definition and relevance of a partial remission. Kidney Int 66: 1199-1205, 2004
14. Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, Baltar J, Fernández-Fresnedo G, Martín C, Pons S, Lorenzo D, Bernis C, Arrizabalaga P, Fernández-Juárez G, Barrio V, Sierra M, Castellanos I, Espinosa M, Rivera F, Oliet A, Fernández-Vega F, Praga M; Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología: Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 21: 697-704, 2010
15. Howman A, Chapman TL, Langdon MM, Ferguson C, Adu D, Feehally J, Gaskin GJ, Jayne DR, O'Donoghue D, Boulton-Jones M, Mathieson PW: Immunosuppression for progressive membranous nephropathy: A UK randomised controlled trial. Lancet 381: 744-751, 2013
16. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, Melis P, Valzorio B, Sasdelli M, Pasquali S, Pozzi C, Piccoli G, Lupo A, Segagni S, Antonucci F, Dugo M, Minari M, Scalia A, Pedrini L, Pisano G, Grassi C, Farina M, Bellazzi R: A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 9: 444-450, 1998
17. BrantenAJ, Reichert LJ, Koene RA,Wetzels JF:Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. QJM 91: 359-366, 1998
18. Kamanamool N, McEvoy M, Attia J, Ingsathit A, Ngamjanyaporn P, Thakkinstian A: Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis. Medicine (Baltimore) 89: 227-235, 2010
19. Lionaki S, Derebail VK, Hogan SL, Barbour S, Lee T, Hladunewich M, Greenwald A, Hu Y, Jennette CE, Jennette JC, Falk RJ, Cattran DC, Nachman PH, Reich HN: Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol 7: 43-51, 2012
20. Bruns FJ, Adler S, Fraley DS, Segel DP: Sustained remission of membranous glomerulonephritis after cyclophosphamide and prednisone. Ann Intern Med 114: 725-730, 1991
21. Knight A, Askling J, Granath F, Sparen P, Ekbom A: Urinary bladder cancer in Wegener's granulomatosis: Risks and relation to cyclophosphamide. Ann Rheum Dis 63: 1307-1311, 2004
22. FaurschouM, Sorensen IJ,Mellemkjaer L, Loft AG, Thomsen BS, Tvede N, Baslund B: Malignancies in Wegener's granulomatosis: Incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35: 100-105, 2008
23. Hofstra JM, Wetzels JF: Alkylating agents in membranous nephropathy: Efficacy proven beyond doubt. Nephrol Dial Transplant 25: 1760-1766, 2010
24. McQuarrie EP, Stirling CM, Geddes CC: Idiopathic membranous nephropathy and nephrotic syndrome: Outcome in the era of evidencebased therapy. Nephrol Dial Transplant 27: 235-242, 2012
25. Bjørneklett R, Vikse BE, Svarstad E, Aasarød K, Bostad L, Langmark F, Iversen BM: Long-term risk of cancer in membranous nephropathy patients. AmJ Kidney Dis 50: 396-403, 2007
26. CattranDC, Pei Y, Greenwood CM, Ponticelli C, Passerini P, Honkanen E: Validation of a predictivemodel of idiopathic membranous nephropathy: Its clinical and research implications. Kidney Int 51: 901-907, 1997
27. Branten AJ, du Buf-Vereijken PW, Klasen IS, Bosch FH, Feith GW, Hollander DA, Wetzels JF: Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: A validation study. J Am Soc Nephrol 16: 169-174, 2005
28. Branten AJ, du Buf-Vereijken PW, Vervloet M, Wetzels JF: Mycophenolate mofetil in idiopathic membranous nephropathy: A clinical trial with comparison to a historic control group treated with cyclophosphamide. AmJ Kidney Dis 50: 248-256, 2007